BRCA1 and ovarian carcinoma: BRCA1/2 mutations constituted approximately 80% of cases in Chinese ovarian cancer patients harboring at least one HRR-related pathogenic mutation (Fig. S2C), with mutually exclusive occurrences of BRCA1/2 mutations (P < 0.001; Fig. S2D).